CIK 0001678660 · Non-accelerated filer<br>Smaller reporting company
Prelude Therapeutics Inc
Sign in to watch- Ticker
- PRLD
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 811384762
- Phone
- (302) 467-1280
- Business address
- 175 INNOVATION BOULEVARD, WILMINGTON, DE, 19805
- Former names
- Prelude Therapeutics Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 62 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-02-07 | Vaddi Krishna CEO | Grant or award · Employee Stock Option (right to buy) | +330,000 | 330,000 | ||
| 2022-12-21 | Chardonnet Laurent Chief Financial Officer | Grant or award · Employee Stock Option (right to buy) | +75,000 | 75,000 | ||
| 2022-12-20 | Vaddi Krishna CEO | Purchase | +19,188 | $5.13 | $98K | 120,665 |
| 2022-12-08 | Chardonnet Laurent Chief Financial Officer | Purchase | +10,000 | $4.76 | $48K | 35,873 |
| 2022-06-17 | Sandor Victor Director | Grant or award · Director Stock Option (Right to Buy) | +34,300 | 34,300 | ||
| 2022-06-17 | FRIEDMAN PAUL A Director | Grant or award · Director Stock Option (Right to Buy) | +34,300 | 34,300 | ||
| 2022-06-17 | Dier Mardi Director | Grant or award · Director Stock Option (Right to Buy) | +34,300 | 34,300 | ||
| 2022-06-17 | Babler Martin Director | Grant or award · Director Stock Option (Right to Buy) | +31,293 | 31,293 | ||
| 2022-06-17 | Bonita David P Director | Grant or award · Director Stock Option (Right to Buy) | +34,300 | 34,300 | ||
| 2022-06-17 | BAKER BROS. ADVISORS LP Director | Grant or award · Non-Qualified Stock Options (right to buy) | +34,300 | 34,300 | ||
| 2022-06-01 | Chardonnet Laurent Chief Financial Officer | Purchase | +10,000 | $4.23 | $42K | 24,500 |
| 2022-05-02 | Huang Jane President, CMO | Grant or award · Employee Stock Option (Right to Buy) | +460,000 | 460,000 | ||
| 2022-05-02 | Huang Jane President, CMO | Grant or award · Restricted Stock Unit | +150,000 | 150,000 | ||
| 2022-04-01 | Combs Andrew EVP, Head of Chemistry | Option exercise · Employee Stock Option (right to buy) | −36,062 | 50,397 | ||
| 2022-03-31 | Combs Andrew EVP, Head of Chemistry | Option exercise | +36,062 | $1.89 | $68K | 304,442 |
| 2022-03-21 | Chardonnet Laurent Chief Financial Officer | Grant or award | +6,500 | $7.51 | $49K | 14,500 |
| 2022-02-15 | Scherle Peggy Chief Scientific Officer | Grant or award · Employee Stock Option (right to buy) | +100,000 | 100,000 | ||
| 2022-02-15 | Chardonnet Laurent Chief Financial Officer | Grant or award · Employee Stock Option (right to buy) | +90,000 | 90,000 | ||
| 2022-02-15 | Vaddi Krishna CEO | Grant or award · Employee Stock Option (right to buy) | +327,900 | 327,900 | ||
| 2022-02-15 | Morosini Deborah EVP, Chief of Clinical Affairs | Grant or award · Employee Stock Option (right to buy) | +90,000 | 90,000 |
Page 7 of 8 · 141 trades